Previous 10 |
Zafgen (NASDAQ: ZFGN ): Q4 GAAP EPS of -$0.39 beats by $0.05. More news on: Zafgen, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies Expanded executive ...
BOSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffr...
BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it wi...
BOSTON, March 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced the appoint...
Shares of Zafgen ( ZFGN ) have risen by 115% since I originally suggested readers take a position in this turnaround idea which was essentially valued at its cash position while targeting large market opportunities with its second generation MetAP2 inhibitor ZGN-1061. After the second quarte...
BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffre...
Zafgen, Inc. (ZFGN) Q2 2018 Earnings Conference Call August 7, 2018, 04:30 PM ET Executives John Woolford - IR, Westwicke Partners Jeffrey Hatfield - CEO Dennis Kim - CMO Patricia Allen - CFO Analysts Edward Tenthoff - Piper Jaffray Jason Butler - JMP Securities Josep...
News, Short Squeeze, Breakout and More Instantly...
Zafgen Company Name:
ZFGN Stock Symbol:
NASDAQ Market:
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chi...
These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for Friedreich’s ataxia Companies to host confere...